Autoimmune-Summaries: Daily Autoimmune Updates at a Glance
03/09/2026
FDA granted Fast Track Designation to YUTREPIA® for the treatment of Raynaud's phenomenon associated with systemic sclerosis. (Ref)
Liquidia Corporation announced that the US FDA had granted Fast Track designation to YUTREPIA® (treprostinil) inhalation powder for the treatment of Raynaud's phenomenon associated with systemic sclerosis (SSc-RP).
The company planned to initiate Ph2a, RE-WARM/ NCT07748000 a dose-finding study of YUTREPIA in SSc-RP, in the fourth quarter of 2026.
RE-WARM is designed to characterize the safety and pharmacodynamics of YUTREPIA in pts with SSc-RP.
The study will also evaluate whether treatment reduces the number, severity and impact of RP attacks.
The study is expected to begin in October 2026, with primary completion targeted for February 2027.


